Literature DB >> 32092584

Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.

Yinjun Lou1, Li Shao2, Liping Mao2, Ying Lu3, Yafang Ma2, Cuihua Fan4, Huifang Jiang5, Jianhu Li2, Jie Jin6.   

Abstract

Entities:  

Year:  2020        PMID： 32092584     DOI： 10.1016/j.leukres.2020.106317

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Alexandra Keller; Daniel Ivanov; Barbara Peter; Daniela Berger; Gabriele Stefanzl; Karin Bauer; Katharina Slavnitsch; Georg Greiner; Karoline V Gleixner; Wolfgang R Sperr; Michael Willmann; Heinz Sill; Peter Bettelheim; Klaus Geissler; Michael Deininger; Thomas Rülicke; Peter Valent
Journal:  Leukemia       Date:  2021-03-30       Impact factor: 12.883

2.  [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].

Authors:  L H Zong; X X Wu; J Zhang; M Y Li; B Q Song; J Y Kong; X Kong; X H Hu; X B Bao; H Y Qiu; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-10-14

Review 3.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

4.  Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.

Authors:  Juan Tong; Na Zhao; Xing Hu; Wen Yao; Yaxin Cheng; Li Zhou; Huilan Liu; Liangquan Geng; Zimin Sun; Changcheng Zheng
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989

5.  Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.

Authors:  Ida Sofie Grønningsæter; Håkon Reikvam; Elise Aasebø; Sushma Bartaula-Brevik; Tor Henrik Tvedt; Øystein Bruserud; Kimberley Joanne Hatfield
Journal:  Cells       Date:  2020-05-07       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.